RESUMO
BACKGROUND AND AIMS: Limited data is available from India on outcome and efficacy of tenofovir and entecavir in hepatitis B virus (HBV)-related cirrhosis when used for prolonged time. We report the long-term efficacy and outcome of these antiviral drugs in patients with chronic HBV infection, with compensated or decompensated cirrhosis. METHODS: We retrospectively analyzed laboratory and clinical data of 400 HBV-related cirrhotic patients without access to liver transplantation, who were treated with tenofovir/entecavir therapy, from January 2007 to January 2014. Two hundred and ten (52.5 %) patients had at least one of the components of decompensation at baseline. Two hundred and twenty (55 %) and 180 (45 %) patients were initiated tenofovir and entecavir, respectively. Follow up period was 45 (12-68) months for tenofovir and 36 (11-60) months for entecavir. RESULTS: At the end of 1 year, levels of HBV DNA <20 IU/mL were achieved in 91.8 % and 88.8 % of patients, and alanine aminotransferase normalized in 54.5 % and 55.5 % of patients who received tenofovir and entecavir, respectively. At the last visit, Child-Turcotte-Pugh scores improved among 29.5 % of patients who received tenofovir, 25 % of those who received entecavir, and remained stable in 61.9 % and 65 % patients, respectively, in both groups. The 5-year cumulative rate of liver decompensation, hepatocellular carcinoma, and cirrhosis-related complications were 3.1 %, 1.9 %, and 2.1 % with an annual incidence of 0.8 %, 0.3 %, and 0.5 % per person-year, respectively. CONCLUSION: Tenofovir and entecavir were effective and potent drugs for prolonged treatment of HBV cirrhosis and improved the overall clinical course.
Assuntos
Antivirais/uso terapêutico , Guanina/análogos & derivados , Hepatite B Crônica/tratamento farmacológico , Cirrose Hepática/tratamento farmacológico , Tenofovir/uso terapêutico , Adulto , Idoso , Antivirais/administração & dosagem , Carcinoma Hepatocelular/etiologia , Carcinoma Hepatocelular/prevenção & controle , Feminino , Seguimentos , Guanina/administração & dosagem , Guanina/uso terapêutico , Hepatite B Crônica/complicações , Humanos , Cirrose Hepática/etiologia , Neoplasias Hepáticas/etiologia , Neoplasias Hepáticas/prevenção & controle , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Tenofovir/administração & dosagem , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
BACKGROUND: Amebic liver abscess (ALA) is a common and serious problem in our country. There are only a few controlled trials on the efficacy and advantages of combination therapy with percutaneous needle aspiration and pharmacotherapy, over pharmacotherapy alone for amebic liver abscess. MATERIAL AND METHODS: This study was conducted to compare the efficacy of two different treatment modalities i.e. drug treatment alone vs. drug treatment and aspiration of abscess cavity in patients with small (up to 5 cm) and large (5 cm to 10 cm) size ALA. This is one of the largest single center, prospective, randomized studies comparing the efficacy of aspiration in ALA. RESULTS: (i) Mean body temperature, liver tenderness, total leukocyte count (TLC), serum alanine aminotransferase (ALT) and liver span were significantly decreased in the aspiration group on days 8 and 15 as compared to non-aspiration group especially in large abscess (5 cm to 10 cm). (ii) Abscess cavity maximum diameter decreased significantly in aspiration group on days 8 and 15, and 1 month & 3 months in large abscess (5cm to 10 cm). CONCLUSIONS: (i) Needle aspiration along with metronidazole hastens clinical improvement especially in large (5 cm up to 10 cm) cavities in patients with ALA. (ii) Aspiration is safe and no major complications occurred. (iii) Hence, combination therapy should be the first choice especially in large ALA (5 cm to 10 cm).
Assuntos
Antiprotozoários/uso terapêutico , Entamebíase/terapia , Abscesso Hepático Amebiano/terapia , Metronidazol/uso terapêutico , Paracentese/métodos , Alanina Transaminase/sangue , Terapia Combinada , Entamebíase/sangue , Entamebíase/patologia , Febre , Humanos , Índia , Contagem de Leucócitos , Fígado/patologia , Abscesso Hepático Amebiano/sangue , Abscesso Hepático Amebiano/patologia , Tamanho do Órgão , Resultado do TratamentoAssuntos
Adenocarcinoma/complicações , Adenocarcinoma/diagnóstico , Equinococose Hepática/complicações , Equinococose Hepática/diagnóstico , Neoplasias Esofágicas/complicações , Neoplasias Esofágicas/diagnóstico , Adenocarcinoma/terapia , Idoso , Diagnóstico Tardio , Diagnóstico Diferencial , Diagnóstico por Imagem , Neoplasias Esofágicas/terapia , Humanos , Achados Incidentais , Masculino , Pessoa de Meia-Idade , Fatores de TempoAssuntos
Colo , Doenças do Colo , Infecções por Spirochaetales , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Criança , Colo/microbiologia , Colo/patologia , Doenças do Colo/diagnóstico , Doenças do Colo/tratamento farmacológico , Doenças do Colo/microbiologia , Doenças do Colo/fisiopatologia , Colonoscopia , Humanos , Masculino , Metronidazol/administração & dosagem , Metronidazol/uso terapêutico , Infecções por Spirochaetales/diagnóstico , Infecções por Spirochaetales/tratamento farmacológico , Infecções por Spirochaetales/microbiologia , Infecções por Spirochaetales/fisiopatologiaRESUMO
We present a rare case of acute pancreatitis in a 50-year-old man with amoebic liver abscess. He had a right lobe liver abscess along with markedly elevated serum lipase and amylase levels and edematous pancreas. Liver abscess was aspirated. The patient was managed conservatively with antibiotics and improved without any complications. Acute pancreatitis associated with ALA is not reported in the literature till date.